Patent: 10,213,485
Summary for Patent: 10,213,485
| Title: | HGF preparation suitable for treatment of neurological disorders |
| Abstract: | The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients. |
| Inventor(s): | Kazuhiro Fukuta, Hayao Inoue |
| Assignee: | Kringle Pharma Inc |
| Application Number: | US15/507,886 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,213,485
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | VECTIBIX | panitumumab | Injection | 125147 | September 27, 2006 | ⤷ Start Trial | 2035-08-27 |
| Seqirus Inc. | AGRIFLU | influenza virus vaccine | Injection | 125297 | November 27, 2009 | ⤷ Start Trial | 2035-08-27 |
| Alexion Pharmaceuticals, Inc. | STRENSIQ | asfotase alfa | Injection | 125513 | October 23, 2015 | ⤷ Start Trial | 2035-08-27 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,213,485
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2958342 | ⤷ Start Trial |
| China | 106714823 | ⤷ Start Trial |
| Denmark | 3192524 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
